| Caralynn Rachel Benoit, MA CCC SLP | |
|
3915 Golden Valley Road, Courage Center, Golden Valley, MN 55422-4298 | |
| (763) 588-0811 | |
| (763) 520-0355 |
| Full Name | Caralynn Rachel Benoit |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3915 Golden Valley Road, Golden Valley, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154417509 | NPI | - | NPPES |
| 4607088 | Other | MEDICA | |
| 58D68BE | Other | BCBS MINNESOTA | |
| HP41502 | Other | HEALTH PARTNERS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 6345 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Caralynn Rachel Benoit, MA CCC SLP 3915 Golden Valley Road, Courage Center, Golden Valley, MN 55422-4298 Ph: (763) 588-0811 | Caralynn Rachel Benoit, MA CCC SLP 3915 Golden Valley Road, Courage Center, Golden Valley, MN 55422-4298 Ph: (763) 588-0811 |
News Archive
Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., announced today that its latest joint venture target, Amarantus BioSciences, Inc., expects to announce the results of a preclinical study evaluating the potential of its new protein therapy as a treatment for Traumatic Brain Injury (TBI).
Fibromyalgia is a condition in which the brain processes pain in an abnormal way, resulting in chronic, widespread muscular-skeletal pain and chronic fatigue. This condition effects millions of Americans and has been poorly understood and under diagnosed, resulting in billions of dollars in cost to our health care system.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Recent federal legislation imposes financial penalties on hospitals that experience excessive patient readmissions within 30 days. A new study published today in the Journal of Hospital Medicine looks at the potential of a program designed to improve the discharge process and prevent avoidable rehospitalizations.
According to a new report from the American Cancer Society, fewer Americans are dying of cancer. The society's annual report on cancer statistics showed that cancer death rates have fallen nearly two percent for both men and women over the past five years. However experts warn that people still need to cut down their cancer risk.
› Verified 4 days ago
Georgette R Danczyk, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3915 Golden Valley Rd, Courage Center, Golden Valley, MN 55422 Phone: 763-588-0811 Fax: 763-520-0355 | |
Anna Smith, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5825 Saint Croix Ave N, Golden Valley, MN 55422 Phone: 612-405-5301 | |
Linda L Richards, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3915 Golden Valley Rd, Golden Valley, MN 55422 Phone: 763-520-0398 | |
Rachell Westby, M.C.D. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3915 Golden Valley Rd, Courage Center, Golden Valley, MN 55422 Phone: 763-230-1337 | |
Christine Ann Wing, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3915 Golden Valley Rd, Golden Valley, MN 55422 Phone: 763-588-0811 Fax: 763-520-0355 | |
David A White, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3915 Golden Valley Road, Courage Center, Golden Valley, MN 55422 Phone: 763-520-0469 Fax: 763-520-0355 |